​

Ionis Pharmaceuticals (IONS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IONS Stock Forecast

Ionis Pharmaceuticals (IONS) stock forecast, based on 32 Wall Street analysts, predicts a 12-month average price target of $81.09, with a high of $96.00 and a low of $65.00. This represents a 11.10% increase from the last price of $72.99.

$30 $44 $58 $72 $86 $100 High: $96 Avg: $81.09 Low: $65 Last Closed Price: $72.99

IONS Stock Rating

Ionis Pharmaceuticals stock's rating consensus is Buy, based on 32 Wall Street analysts. The breakdown includes 1 Strong Buy (3.12%), 19 Buy (59.38%), 12 Hold (37.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 32 12 19 1 Strong Sell Sell Hold Buy Strong Buy

IONS Price Target Upside V Benchmarks

TypeNameUpside
StockIonis Pharmaceuticals11.10%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts31818
Avg Price Target$82.33$74.39$74.39
Last Closing Price$72.99$72.99$72.99
Upside/Downside12.80%1.92%1.92%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 258107--25
Sep, 2581171-27
Aug, 2581171-27
Jul, 256127-126
Jun, 255128-126
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 16, 2025Morgan Stanley$90.00$72.3924.33%23.30%
Oct 08, 2025Justin KimOppenheimer$90.00$68.9430.55%23.30%
Oct 06, 2025Stifel Nicolaus$67.00$69.15-3.11%-8.21%
Sep 26, 2025Goldman Sachs$65.00$63.432.48%-10.95%
Sep 23, 2025Gena WangBarclays$82.00$61.3633.64%12.34%
Sep 22, 2025Gary NachmanRaymond James$75.00$61.3622.23%2.75%
Sep 04, 2025RBC Capital$80.00$59.3534.79%9.60%
Sep 03, 2025Kostas BiliourisBMO Capital$70.00$60.4915.72%-4.10%
Sep 02, 2025Gena WangBarclays$78.00$57.4935.68%6.86%
Sep 02, 2025Michael UlzMorgan Stanley$71.00$57.4923.50%-2.73%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 16, 2025Morgan StanleyOverweightOverweighthold
Oct 08, 2025OppenheimerOutperformOutperformhold
Sep 26, 2025Goldman SachsSellNeutralupgrade
Sep 23, 2025Morgan StanleyOverweightOverweighthold
Sep 23, 2025GuggenheimBuyBuyhold
Sep 23, 2025BarclaysOverweightOverweighthold
Sep 22, 2025Raymond JamesStrong BuyStrong Buyhold
Sep 04, 2025RBC CapitalOutperformOutperformhold
Sep 03, 2025BMO CapitalMarket PerformOutperformupgrade
Sep 02, 2025Morgan StanleyOverweightOverweighthold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.49$-0.21$-1.90$-2.56$-3.04----
Avg Forecast$-0.52$-1.45$-2.49$-3.28$-3.48$-3.70$-2.77$-1.10$0.74
High Forecast$-0.43$-1.19$-1.93$-2.81$-3.22$-2.51$-1.37$0.63$1.00
Low Forecast$-0.71$-1.98$-3.17$-3.55$-3.69$-4.63$-4.44$-2.51$0.51
Surprise %571.15%-85.52%-23.69%-21.95%-12.64%----

Revenue Forecast

$0 $500M $1B $2B $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$729.00M$810.00M$587.00M$787.65M$705.14M----
Avg Forecast$712.45M$650.76M$583.98M$637.10M$617.72M$670.75M$878.39M$1.26B$1.73B
High Forecast$914.65M$835.45M$707.22M$677.83M$672.60M$746.22M$919.59M$1.30B$2.19B
Low Forecast$614.36M$561.15M$482.28M$588.31M$595.85M$600.55M$837.19M$1.21B$1.32B
Surprise %2.32%24.47%0.52%23.63%14.15%----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-487.00M$-29.00M$-270.00M$-366.29M$-453.90M----
Avg Forecast$-257.28M$390.43M$303.04M$-366.29M$-494.61M$-603.06M$-421.47M$-140.21M$105.64M
High Forecast$-205.82M$557.81M$471.95M$-133.57M$-461.54M$-358.99M$-196.70M$90.77M$142.72M
Low Forecast$-308.74M$223.04M$134.13M$-599.01M$-527.68M$-662.75M$-635.48M$-359.46M$73.45M
Surprise %89.29%-107.43%-189.10%--8.23%----

IONS Forecast FAQ

Is Ionis Pharmaceuticals stock a buy?

Ionis Pharmaceuticals stock has a consensus rating of Buy, based on 32 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 19 Buy, 12 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Ionis Pharmaceuticals is a favorable investment for most analysts.

What is Ionis Pharmaceuticals's price target?

Ionis Pharmaceuticals's price target, set by 32 Wall Street analysts, averages $81.09 over the next 12 months. The price target range spans from $65 at the low end to $96 at the high end, suggesting a potential 11.10% change from the previous closing price of $72.99.

How does Ionis Pharmaceuticals stock forecast compare to its benchmarks?

Ionis Pharmaceuticals's stock forecast shows a 11.10% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Ionis Pharmaceuticals over the past three months?

  • October 2025: 32.00% Strong Buy, 40.00% Buy, 28.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 29.63% Strong Buy, 40.74% Buy, 25.93% Hold, 3.70% Sell, 0% Strong Sell.
  • August 2025: 29.63% Strong Buy, 40.74% Buy, 25.93% Hold, 3.70% Sell, 0% Strong Sell.

What is Ionis Pharmaceuticals’s EPS forecast?

Ionis Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.7, marking a 21.71% increase from the reported $-3.04 in 2024. Estimates for the following years are $-2.77 in 2026, $-1.1 in 2027, and $0.74 in 2028.

What is Ionis Pharmaceuticals’s revenue forecast?

Ionis Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $670.75M, reflecting a -4.88% decrease from the reported $705.14M in 2024. The forecast for 2026 is $878.39M, followed by $1.26B for 2027, and $1.73B for 2028.

What is Ionis Pharmaceuticals’s net income forecast?

Ionis Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-603M, representing an 32.86% increase from the reported $-454M in 2024. Projections indicate $-421M in 2026, $-140M in 2027, and $105.64M in 2028.